Literature DB >> 7881295

The natural history of type I (severe) spinal muscular atrophy.

N H Thomas1, V Dubowitz.   

Abstract

The clinical features of 36 patients who satisfied the diagnostic criteria for type I (severe) spinal muscular atrophy (Werdnig-Hoffmann disease) are reported. Survival data for both the whole cohort and for groups within the cohort subdivided on the age of onset are presented. These data suggest that the patients with onset at birth or within the first 2 months of life have a more uniformly poor prognosis with earlier death. This is of potential importance in any therapeutic trials in the future whose outcome may be based on length of survival.

Entities:  

Mesh:

Year:  1994        PMID: 7881295     DOI: 10.1016/0960-8966(94)90090-6

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  21 in total

Review 1.  Ethics and decision making in end stage lung disease.

Authors:  A K Simonds
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

Review 2.  Spinal Muscular Atrophy.

Authors:  Stephen J Kolb; John T Kissel
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

Review 3.  Small Molecules in Development for the Treatment of Spinal Muscular Atrophy.

Authors:  Alyssa N Calder; Elliot J Androphy; Kevin J Hodgetts
Journal:  J Med Chem       Date:  2016-08-16       Impact factor: 7.446

4.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

5.  DNA Damage Response and DNA Repair in Skeletal Myocytes From a Mouse Model of Spinal Muscular Atrophy.

Authors:  Saniya Fayzullina; Lee J Martin
Journal:  J Neuropathol Exp Neurol       Date:  2016-07-24       Impact factor: 3.685

6.  Observational study of spinal muscular atrophy type I and implications for clinical trials.

Authors:  Richard S Finkel; Michael P McDermott; Petra Kaufmann; Basil T Darras; Wendy K Chung; Douglas M Sproule; Peter B Kang; A Reghan Foley; Michelle L Yang; William B Martens; Maryam Oskoui; Allan M Glanzman; Jean Flickinger; Jacqueline Montes; Sally Dunaway; Jessica O'Hagen; Janet Quigley; Susan Riley; Maryjane Benton; Patricia A Ryan; Megan Montgomery; Jonathan Marra; Clifton Gooch; Darryl C De Vivo
Journal:  Neurology       Date:  2014-07-30       Impact factor: 9.910

Review 7.  Spinal muscular atrophy: Broad disease spectrum and sex-specific phenotypes.

Authors:  Natalia N Singh; Shaine Hoffman; Prabhakara P Reddi; Ravindra N Singh
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2021-01-05       Impact factor: 5.187

8.  Awareness screening and referral patterns among pediatricians in the United States related to early clinical features of spinal muscular atrophy (SMA).

Authors:  Mary Curry; Rosángel Cruz; Lisa Belter; Mary Schroth; Megan Lenz; Jill Jarecki
Journal:  BMC Pediatr       Date:  2021-05-17       Impact factor: 2.125

9.  Survival analysis of spinal muscular atrophy type I.

Authors:  Hyun Bin Park; Soon Min Lee; Jin Sung Lee; Min Soo Park; Kook In Park; Ran Namgung; Chul Lee
Journal:  Korean J Pediatr       Date:  2010-11-30

10.  Drug treatment for spinal muscular atrophy type I.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2019-12-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.